Literature DB >> 28850858

Associations between fine particulate matter and mortality in the 2001 Canadian Census Health and Environment Cohort.

Lauren L Pinault1, Scott Weichenthal2, Daniel L Crouse3, Michael Brauer4, Anders Erickson4, Aaron van Donkelaar5, Randall V Martin6, Perry Hystad7, Hong Chen8, Philippe Finès9, Jeffrey R Brook10, Michael Tjepkema9, Richard T Burnett11.   

Abstract

BACKGROUND: Large cohort studies have been used to characterise the association between long-term exposure to fine particulate matter (PM2.5) air pollution with non-accidental, and cause-specific mortality. However, there has been no consensus as to the shape of the association between concentration and response.
METHODS: To examine the shape of this association, we developed a new cohort based on respondents to the 2001 Canadian census long-form. We applied new annual PM2.5 concentration estimates based on remote sensing and ground measurements for Canada at a 1km spatial scale from 1998 to 2011. We followed 2.4 million respondents who were non-immigrants aged 25-90 years and did not reside in an institution over a 10 year period for mortality. Exposures were assigned as a 3-year mean prior to the follow-up year. Income tax files were used to account for residential mobility among respondents using postal codes, with probabilistic imputation used for missing postal codes in the tax data. We used Cox survival models to determine hazard ratios (HRs) for cause-specific mortality. We also estimated Shape Constrained Health Impact Functions (a concentration-response function) for selected causes of death.
RESULTS: In models stratified by age, sex, airshed, and population centre size, and adjusted for individual and neighbourhood socioeconomic variables, HR estimates for non-accidental mortality were HR = 1.18 (95% CI: 1.15-1.21) per 10μg/m3 increase in concentration. We observed higher HRs for cardiovascular disease (HR=1.25; 95% CI: 1.19-1.31), cardio-metabolic disease (HR = 1.27; 95% CI: 1.21-1.33), ischemic heart disease (HR = 1.36; 95% CI: 1.28-1.44) and chronic obstructive pulmonary disease (COPD) mortality (HR = 1.24; 95% CI: 1.11-1.39) compared to HR for all non-accidental causes of death. For non-accidental, cardio-metabolic, ischemic heart disease, respiratory and COPD mortality, the shape of the concentration-response curve was supra-linear, with larger differences in relative risk for lower concentrations. For both pneumonia and lung cancer, there was some suggestion that the curves were sub-linear.
CONCLUSIONS: Associations between ambient concentrations of fine particulate matter and several causes of death were non-linear for each cause of death examined.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular; Cohort; Mortality; PM(2.5); Respiratory

Mesh:

Substances:

Year:  2017        PMID: 28850858     DOI: 10.1016/j.envres.2017.08.037

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  38 in total

1.  A multiphase CMAQ version 5.0 adjoint.

Authors:  Shunliu Zhao; Matthew G Russell; Amir Hakami; Shannon L Capps; Matthew D Turner; Daven K Henze; Peter B Percell; Jaroslav Resler; Huizhong Shen; Armistead G Russell; Athanasios Nenes; Amanda J Pappin; Sergey L Napelenok; Jesse O Bash; Kathleen M Fahey; Gregory R Carmichael; Charles O Stanier; Tianfeng Chai
Journal:  Geosci Model Dev       Date:  2020-07-02       Impact factor: 6.135

Review 2.  Transforming Our Cities: Best Practices Towards Clean Air and Active Transportation.

Authors:  Andrew Glazener; Haneen Khreis
Journal:  Curr Environ Health Rep       Date:  2019-03

3.  Quantitative Characterization of Uncertainty in the Concentration-Response Relationship between Long-Term PM2.5 Exposure and Mortality at Low Concentrations.

Authors:  Evan Coffman; Richard T Burnett; Jason D Sacks
Journal:  Environ Sci Technol       Date:  2020-08-06       Impact factor: 9.028

4.  Chronic Effects of High Fine Particulate Matter Exposure on Lung Cancer in China.

Authors:  Jianxin Li; Xiangfeng Lu; Fangchao Liu; Fengchao Liang; Keyong Huang; Xueli Yang; Qingyang Xiao; Jichun Chen; Xiaoqing Liu; Jie Cao; Shufeng Chen; Chong Shen; Ling Yu; Fanghong Lu; Xianping Wu; Liancheng Zhao; Xigui Wu; Ying Li; Dongsheng Hu; Jianfeng Huang; Meng Zhu; Yang Liu; Hongbing Shen; Dongfeng Gu
Journal:  Am J Respir Crit Care Med       Date:  2020-12-01       Impact factor: 21.405

Review 5.  Particulate matter in COPD pathogenesis: an overview.

Authors:  Manpreet Kaur; Jitender Chandel; Jai Malik; Amarjit S Naura
Journal:  Inflamm Res       Date:  2022-06-16       Impact factor: 6.986

Review 6.  Climate change and cardiovascular disease: implications for global health.

Authors:  Haitham Khraishah; Barrak Alahmad; Robert L Ostergard; Abdelrahman AlAshqar; Mazen Albaghdadi; Nirupama Vellanki; Mohammed M Chowdhury; Sadeer G Al-Kindi; Antonella Zanobetti; Antonio Gasparrini; Sanjay Rajagopalan
Journal:  Nat Rev Cardiol       Date:  2022-06-07       Impact factor: 49.421

7.  Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019.

Authors: 
Journal:  Lancet Planet Health       Date:  2022-07

8.  Ambient air pollution, healthy diet and vegetable intakes, and mortality: a prospective UK Biobank study.

Authors:  Mengying Wang; Tao Zhou; Qiying Song; Hao Ma; Yonghua Hu; Yoriko Heianza; Lu Qi
Journal:  Int J Epidemiol       Date:  2022-08-10       Impact factor: 9.685

9.  Interventions to reduce ambient particulate matter air pollution and their effect on health.

Authors:  Jacob Burns; Hanna Boogaard; Stephanie Polus; Lisa M Pfadenhauer; Anke C Rohwer; Annemoon M van Erp; Ruth Turley; Eva Rehfuess
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

Review 10.  Links between chronic exposure to outdoor air pollution and cardiovascular diseases: a review.

Authors:  Ewa Konduracka; Paweł Rostoff
Journal:  Environ Chem Lett       Date:  2022-04-25       Impact factor: 13.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.